TY - JOUR
T1 - The Use of Risk-Enhancing Factors to Personalize ASCVD Risk Assessment
T2 - Evidence and Recommendations from the 2018 AHA/ACC Multi-Society Cholesterol Guidelines
AU - Agarwala, Anandita
AU - Liu, Jing
AU - Ballantyne, Christie M.
AU - Virani, Salim S.
N1 - Funding Information:
Funding This study was supported by Abbott Diagnostic, Akcea, Amgen, Esperion, Novartis, Regeneron, Roche Diagnostic, Sanofi-Synthelabo, NIH, AHA, and ADA. All were paid to institution, not individual.
Funding Information:
Conflict of Interest Anandita Agarwala MD, Jing Liu MD, and Salim S. Virani MD declare that they have no conflict of interest. Dr. Virani was supported by research funding from the Department of Veterans Affairs Health Services Research & Development Service Investigator Initiated Grant, World Heart Federation, and the Jooma and Tahir Family. Dr. Ballantyne was supported by R01-HL134320.
Publisher Copyright:
© 2019, This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
PY - 2019/7/1
Y1 - 2019/7/1
N2 - Purpose of Review: In 2018, the AHA/ACC Multi-Society Cholesterol Guidelines introduced the novel concept of risk-enhancing factors to be used as a supplement to the pooled cohort risk equations to personalize atherosclerotic cardiovascular disease risk assessment in primary prevention. In this review, we discuss the rationale and evidence behind each of the risk-enhancing factors to help clinicians perform a more personalized cardiovascular risk assessment. Recent Findings: The risk-enhancing factors are high-risk features that may guide the use of lipid-lowering therapy particularly in intermediate and select borderline-risk patients. For the purpose of this review, these factors are divided into five categories: (i) race and genetics, (ii) conditions specific to women, (iii) lipid-related risk, (iv) concurrent high-risk medical conditions, and (v) biomarkers. Summary: The addition of the risk-enhancing factors to the pooled cohort equations provides a more individualized and comprehensive approach to cardiovascular disease risk assessment.
AB - Purpose of Review: In 2018, the AHA/ACC Multi-Society Cholesterol Guidelines introduced the novel concept of risk-enhancing factors to be used as a supplement to the pooled cohort risk equations to personalize atherosclerotic cardiovascular disease risk assessment in primary prevention. In this review, we discuss the rationale and evidence behind each of the risk-enhancing factors to help clinicians perform a more personalized cardiovascular risk assessment. Recent Findings: The risk-enhancing factors are high-risk features that may guide the use of lipid-lowering therapy particularly in intermediate and select borderline-risk patients. For the purpose of this review, these factors are divided into five categories: (i) race and genetics, (ii) conditions specific to women, (iii) lipid-related risk, (iv) concurrent high-risk medical conditions, and (v) biomarkers. Summary: The addition of the risk-enhancing factors to the pooled cohort equations provides a more individualized and comprehensive approach to cardiovascular disease risk assessment.
KW - Atherosclerotic cardiovascular disease
KW - Biomarkers
KW - Lipid
KW - Race and genetics
KW - Risk assessment
KW - Risk-enhancing factors
UR - http://www.scopus.com/inward/record.url?scp=85066130900&partnerID=8YFLogxK
U2 - 10.1007/s12170-019-0616-y
DO - 10.1007/s12170-019-0616-y
M3 - Review article
AN - SCOPUS:85066130900
SN - 1932-9520
VL - 13
JO - Current Cardiovascular Risk Reports
JF - Current Cardiovascular Risk Reports
IS - 7
M1 - 18
ER -
